NCT04212013 - A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 23, 2019

Primary Completion Date

March 18, 2027

Study Completion Date

March 18, 2027

Conditions

Marginal Zone Lymphoma

Interventions

DRUG

Ibrutinib

Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.

DRUG

Rituximab

Will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 of cycle 1

OTHER

Placebo

Placebo capsules will be similarly dosed at 4 capsules daily.

Trial Locations (10)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester, Harrison

Memorial Sloan Kettering Nassau, Uniondale

Memorial Sloan Kettering Commack, Commack

George Washington Cancer Center, Washington D.C.

Moffitt Cancer Center, Tampa

Mayo Clinic Cancer Center, Rochester

Memorial Sloan Kettering Basking Ridge, Basking Ridge

Memorial Sloan Kettering Monmouth, Middletown

Memorial Sloan Kettering Bergen, Montvale